^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD22 positive

    i
    Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
    Entrez ID:
    933
    Related biomarkers:
    Expression
    Apply
    Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (A041703) (NCT03739814)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    05/08/2019
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    ABL1 • BCR • CD22
    |
    CD22 positive • CD22 expression
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT05687032)
    Phase 4
    Pfizer
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    02/24/2023
    Primary completion :
    08/07/2024
    Completion :
    11/07/2025
    CD22
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (NCT03150693)
    Phase 3
    Alliance for Clinical Trials in Oncology
    Suspended
    Last update posted :
    05/23/2024
    Initiation :
    06/01/2017
    Primary completion :
    03/01/2025
    Completion :
    08/01/2025
    ABL1 • BCR • CD20 • CD22 • ITGB1
    |
    CD20 positive • CD22 positive
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous
    Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (NCT05303792)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    02/27/2023
    Primary completion :
    05/31/2025
    Completion :
    05/01/2028
    CD20 • CD22
    |
    CD20 expression • CD22 positive
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection
    A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to (EU PIP Study) (NCT05748171)
    Phase 2
    Pfizer
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    05/17/2023
    Primary completion :
    07/11/2028
    Completion :
    07/09/2031
    TP53 • KMT2A • CD22 • TCF3 • PBX1
    |
    KMT2A rearrangement • MLL rearrangement • CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). (NCT06078306)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    04/20/2024
    Primary completion :
    09/10/2024
    Completion :
    09/10/2025
    CD22
    |
    CD22 positive
    |
    Venclexta (venetoclax) • azacitidine
    Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO (INO-FIRST) (NCT06025682)
    Phase N/A
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    04/04/2024
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    CD22
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (IRB-50836) (NCT04088890)
    Phase 1
    Stanford University
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    09/12/2019
    Primary completion :
    12/30/2024
    Completion :
    12/30/2037
    CD22
    |
    CD22 positive • CD22 expression • CD20 negative
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)
    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (NCT03104491)
    Phase 1/2
    Leland Metheny
    Recruiting
    Last update posted :
    02/29/2024
    Initiation :
    07/31/2017
    Primary completion :
    05/01/2024
    Completion :
    05/01/2026
    BCL2 • BCL6 • CD22
    |
    BCL6 rearrangement • CD22 positive • BCL2 rearrangement
    |
    Besponsa (inotuzumab ozogamicin)
    CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (NCT04088864)
    Phase 1
    Stanford University
    Active, not recruiting
    Last update posted :
    02/12/2024
    Initiation :
    01/10/2020
    Primary completion :
    10/31/2023
    Completion :
    09/10/2036
    CD22
    |
    CD22 positive • CD22 expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)
    Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma (NCT04715217)
    Phase 1/2
    Shanxi Province Cancer Hospital
    Recruiting
    Last update posted :
    12/29/2023
    Initiation :
    01/04/2021
    Primary completion :
    10/31/2024
    Completion :
    10/31/2025
    CD22
    |
    CD22 positive
    |
    cyclophosphamide • CD19-CD22 CAR-T • cyclophosphamide intravenous
    Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL (NCT03919526)
    Phase 1
    Shanghai General Hospital, Shanghai Jiao Tong U...
    Completed
    Last update posted :
    12/08/2023
    Initiation :
    08/11/2019
    Primary completion :
    11/01/2023
    Completion :
    11/01/2023
    CD22
    |
    CD19 positive • CD22 positive
    |
    cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
    A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients (NCT03677596)
    Phase 4
    Pfizer
    Completed
    Last update posted :
    11/22/2023
    Initiation :
    07/01/2019
    Primary completion :
    09/21/2022
    Completion :
    05/26/2023
    CD22
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia (NCT06081478)
    Phase 2
    Beijing Tongren Hospital
    Recruiting
    Last update posted :
    10/13/2023
    Initiation :
    01/18/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    CD22
    |
    CD22 positive
    Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL 001) (NCT03962465)
    Phase 1
    University of Virginia
    Active, not recruiting
    Last update posted :
    08/22/2023
    Initiation :
    07/22/2022
    Primary completion :
    07/15/2023
    Completion :
    07/01/2026
    CD22
    |
    CD22 positive
    |
    cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • Oncaspar liquid (pegaspargase)
    Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (NCT04029038)
    Phase 1/2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    08/21/2023
    Initiation :
    05/15/2019
    Primary completion :
    11/16/2022
    Completion :
    11/16/2022
    CD22
    |
    CD22 positive
    |
    cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous
    A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment (NCT05597085)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    08/08/2023
    Initiation :
    03/08/2023
    Primary completion :
    07/04/2023
    Completion :
    07/04/2023
    CD22
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    Study of Sequential CAR-T Cell Treating Leukemia Children (NCT04340154)
    Phase 2
    Beijing Boren Hospital
    Active, not recruiting
    Last update posted :
    08/02/2023
    Initiation :
    05/01/2020
    Primary completion :
    05/01/2024
    Completion :
    11/01/2024
    ABL1 • CD22
    |
    CD19 expression • CD22 positive • CD22 expression
    |
    cyclophosphamide
    Venetoclax Plus Inotuzumab for B-ALL (NCT05016947)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    07/18/2023
    Initiation :
    09/24/2021
    Primary completion :
    07/23/2024
    Completion :
    06/23/2026
    CD22
    |
    CD22 positive
    |
    Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin)
    Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCT03991884)
    Phase 1
    University of Washington
    Completed
    Last update posted :
    07/06/2023
    Initiation :
    09/24/2019
    Primary completion :
    10/20/2022
    Completion :
    06/28/2023
    CD22
    |
    CD22 positive • CD22 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • cyclophosphamide intravenous
    S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia (NCT01925131)
    Phase 1
    SWOG Cancer Research Network
    Completed
    Last update posted :
    05/03/2023
    Initiation :
    06/13/2014
    Primary completion :
    01/01/2022
    Completion :
    01/01/2023
    CD22 • CD4
    |
    CD22 positive
    |
    cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • cyclophosphamide intravenous
    Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04648475)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    08/25/2020
    Primary completion :
    12/31/2023
    Completion :
    07/01/2024
    IL6 • CD22 • IL10
    |
    CD19 expression • CD22 positive • CD22 expression • IL10 elevation
    CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04649983)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    09/01/2019
    Primary completion :
    12/31/2023
    Completion :
    07/01/2024
    CD22
    |
    CD19 expression • CD22 positive • CD22 expression
    a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (NCT04782193)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    05/23/2021
    Primary completion :
    12/31/2023
    Completion :
    07/01/2024
    IL6 • CD22 • IL10
    |
    CD19 expression • CD22 positive • CD22 expression • IL10 elevation
    |
    CD19 and CD22 targeted prime CAR-T
    To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors (NCT05388695)
    Phase 1
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    01/13/2023
    Initiation :
    04/08/2022
    Primary completion :
    03/30/2025
    Completion :
    05/01/2025
    CD20 • CD22
    |
    CD20 positive • CD19 positive • CD22 positive • CD19 positive + CD20 positive
    Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients (NCT05651178)
    Phase 1
    Hrain Biotechnology Co., Ltd.
    Recruiting
    Last update posted :
    12/14/2022
    Initiation :
    08/12/2022
    Primary completion :
    08/31/2024
    Completion :
    08/31/2025
    IL6 • CD22 • IL15
    |
    CD22 positive
    |
    anti-CD19/CD22 CAR-T cells
    Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (NCT04340167)
    Phase 2
    Beijing Boren Hospital
    Recruiting
    Last update posted :
    08/15/2022
    Initiation :
    05/01/2020
    Primary completion :
    05/01/2024
    Completion :
    10/01/2024
    ABL1 • CD22
    |
    CD22 positive • CD22 expression
    |
    cyclophosphamide • Anti-CD22 CAR-T Cells
    Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia (NCT05225831)
    Phase 1
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    02/07/2022
    Initiation :
    08/15/2021
    Primary completion :
    08/01/2023
    Completion :
    11/01/2023
    IFNG • IL6 • TNFA • CD22 • IL10
    |
    CD19 positive • CD22 positive
    |
    cyclophosphamide • fludarabine IV
    To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. (NCT05223686)
    Phase 1
    Hrain Biotechnology Co., Ltd.
    Not yet recruiting
    Last update posted :
    02/04/2022
    Initiation :
    02/10/2022
    Primary completion :
    06/10/2023
    Completion :
    03/10/2025
    IL6 • CD22 • IL15
    |
    CD22 positive
    |
    anti-CD19/CD22 CAR-T cells
    Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (NCT03851081)
    Phase 1b/2
    Roswell Park Cancer Institute
    Withdrawn
    Last update posted :
    01/28/2022
    Initiation :
    01/21/2021
    Primary completion :
    01/21/2023
    Completion :
    01/21/2024
    CD22
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
    Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL (NCT04788472)
    Phase 1/2
    Zhejiang University
    Recruiting
    Last update posted :
    03/09/2021
    Initiation :
    03/05/2021
    Primary completion :
    03/05/2024
    Completion :
    03/05/2025
    CD22
    |
    CD22 positive
    |
    CD19/CD22 CAR-T cell therapy
    Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies (NCT03262298)
    Phase 1/2
    Affiliated Hospital to Academy of Military Medi...
    Recruiting
    Last update posted :
    02/09/2021
    Initiation :
    08/20/2017
    Primary completion :
    08/20/2021
    Completion :
    08/20/2022
    CD22
    |
    CD22 positive
    |
    CART22
    Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL (NCT04740203)
    Phase 1/2
    Zhejiang University
    Recruiting
    Last update posted :
    02/05/2021
    Initiation :
    01/31/2021
    Primary completion :
    01/31/2024
    Completion :
    01/31/2025
    CD22
    |
    CD22 positive
    |
    CD19 targeted CAR-T • CD19/CD22 CAR-T cell therapy
    Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia (NCT04714593)
    Phase 1/2
    Shanxi Province Cancer Hospital
    Recruiting
    Last update posted :
    01/22/2021
    Initiation :
    01/15/2021
    Primary completion :
    12/31/2021
    Completion :
    12/31/2023
    IFNG • IL6 • TNFA • CD22 • IL2 • IL10
    |
    CD22 positive
    |
    cyclophosphamide • CD19-CD22 CAR-T • cyclophosphamide intravenous
    Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (NCT02581878)
    Phase 1
    Bayer
    Completed
    Last update posted :
    11/25/2020
    Initiation :
    11/20/2015
    Primary completion :
    11/11/2019
    Completion :
    11/26/2019
    CD22
    |
    CD22 positive
    |
    epratuzumab-thorium-227 (BAY1862864)
    Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04546906)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    09/14/2020
    Initiation :
    09/01/2020
    Primary completion :
    09/01/2022
    Completion :
    12/01/2022
    IFNG • IL6 • TNFA • CD22 • IL10
    |
    CD22 positive
    |
    cyclophosphamide • SENL-B19 • Senl_22
    A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL (NCT04412174)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Not yet recruiting
    Last update posted :
    06/02/2020
    Initiation :
    06/01/2020
    Primary completion :
    12/01/2022
    Completion :
    12/01/2022
    CD22
    |
    CD22 positive • CD22 expression • CD20 negative
    |
    GC022F • SENL-B19
    Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma (NCT01055496)
    Phase 1
    Pfizer
    Completed
    Last update posted :
    08/02/2019
    Initiation :
    03/01/2010
    Primary completion :
    07/01/2013
    Completion :
    03/01/2014
    CD22
    |
    CD22 positive
    |
    cisplatin • gemcitabine • Rituxan (rituximab) • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • dexamethasone
    Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab (NCT00724971)
    Phase 1
    Pfizer
    Completed
    Last update posted :
    03/15/2019
    Initiation :
    07/04/2008
    Primary completion :
    03/10/2010
    Completion :
    03/10/2010
    CD20 • CD22
    |
    CD20 positive • CD22 positive
    |
    Rituxan (rituximab) • Besponsa (inotuzumab ozogamicin)